IBAB Ion Beam Applications SA

IBA - Regulated Information

IBA - Regulated Information

(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings)

Louvain-la-Neuve, Belgium, October 1st, 2024 06:00

Summary of the notification

IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 26, 2024.

In its notification, Vallcara Limited indicated that following an acquisition of securities or voting rights. Its total participation in IBA SA increased and its participation in IBA shares with voting rights crossed the threshold of 3% on 24/09/2024.

Content of the notification

  • Reason for the notification: Acquisition or disposal of securities or voting rights
  • Notification by: A parent company or controlling person
  • Persons subject to the notification requirement:
  • Date on which the threshold is crossed: 24/09/2024
  • Threshold crossed (in %) : 3%
  • Denominator : 40.595.290
  • Notified details: (extract of the received notification form)
  • Full chain of controlled undertakings through which the holding is effectively held

Vallcara Limited is 100% owned by Vallgesa Limited (C 58154), a company registered in Malta. Vallgesa Limited is not a controlled entity.

  • Additional information

Vallcara Limited has reached the 3% notification threshold following the acquisition of shares. Vallcara Limited is the investment manager who can exercise voting rights at its discretion in the absence of specific.

  • About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2.000 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at:

For further information, please contact:

Valérie Van Impe

Paralegal



 

Attachment



EN
01/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Michiel Declercq
  • Wim Lewi
Guy Sips ... (+11)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Lynn Hautekeete
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi

Dynamic Top Pick List Update October 2024 – Adding NN Group

We maintain a defensive stance on the market for 2H24. The long anticipated expectations for interest rate cuts by central banks will finally come to pass. The election fever in the US is reaching boiling point and the conversations are becoming more polarised than before. Also corporate profit growth in Europe slows and the French elections have cast a negative spell. In Germany by-elections in the Eastern part showed a shift to extreme right and left that will make budget decisions even more ...

 PRESS RELEASE

IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to cr...

IBA and Jules Bordet Institute to lead IHI project Accelerate.EU to create complete Astatine-211 value chain A EUR 16 million Initiative to Establish Strategic EU Autonomy in Alpha Therapies for Cancer Louvain-la-Neuve, Belgium, October 3, 2024 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the European Commission has approved the financing of the Accelerate.EU project launching on October 1, 2024. IBA’s key role in this new project...

 PRESS RELEASE

IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU ...

IBA et l'Institut Jules Bordet piloteront le projet IHI Accelerate.EU pour créer une chaîne de valeur complète pour l'Astate-211 Une initiative de 16 millions d'euros pour établir l'autonomie stratégique de l'UE en matière de thérapies alpha contre le cancer Louvain-la-Neuve, Belgique, 3 octobre 2024 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial de la technologie d’accélération de particules et le premier fournisseur mondial de solutions de production de radiopharmaceutiques, annonce aujourd’hui que la Commission européenne a approuvé le financement du projet Accelerate.E...

 PRESS RELEASE

IBA - Regulated Information

IBA - Regulated Information (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, October 1st, 2024 06:00 Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on September 26, 2024. In its notification, Vallcara Limited indicate...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch